Erlotinib
- Generic Name
- Erlotinib
- Brand Names
- Tarceva
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23N3O4
- CAS Number
- 183321-74-6
- Unique Ingredient Identifier
- J4T82NDH7E
- Background
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion...
- Indication
Erlotinib is indicated for:
The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.
- Associated Conditions
- Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
- Associated Therapies
- -
Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2013-05-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 62
- Registration Number
- NCT00242502
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2017-12-26
- Target Recruit Count
- 57
- Registration Number
- NCT00230126
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 94
- Registration Number
- NCT00193258
Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-09-17
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00193622
Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2013-10-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 282
- Registration Number
- NCT00147537
- Locations
- 🇪🇸
Pfizer Investigational Site, Sevilla, Spain
Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- David M. Brizel, MD
- Target Recruit Count
- 28
- Registration Number
- NCT00140556
- Locations
- 🇺🇸
Department of Radiation Oncology; Duke University Medical Center, Durham, North Carolina, United States
Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Pasi A. Janne, MD, PhD
- Target Recruit Count
- 84
- Registration Number
- NCT00137839
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma
- Conditions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2011-12-26
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 37
- Registration Number
- NCT00137826
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2012-05-28
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 40
- Registration Number
- NCT00130520
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-08-04
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 188
- Registration Number
- NCT00126581
- Locations
- 🇺🇸
University Medical Center of Southern Nevada, Las Vegas, Nevada, United States
🇺🇸Kaiser Permanente-San Diego Mission, San Diego, California, United States
🇺🇸Veterans Administration-San Diego Medical Center, San Diego, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.